Cannabis company Emerald Health Therapeutics Inc’s (CVE:EMH) (OTCQX:EMHTF) joint venture, Emerald Health Naturals has received products licenses and natural products numbers from Health Canada for its Endo product line.
The line of nutritional products was developed by Emerald Health Bioceuticals Inc alongside its scientific advisors.
The products, including Endo Sleep, Endo Inflame, Endo Brain, Endo Bliss and Endo Calm, were designed to treat stress, anxiety, restless sleep, pain and other conditions using non-cannabis ingredients.
“We have the unique opportunity to brand Emerald through EHN’s offering of the Endo product line through a number of valuable sales channels that are frequently visited by cannabis users but which cannot currently sell cannabis products,” said Executive Chairman Avtar Dhillon.
The line is expected to launch in mid-2019 and will be available in natural health stores, grocery stores and pharmacies.
Dhillon said that Emerald will be well-positioned to add cannabinoid compounds to Endo products if CBD and other non-psychoactive cannabinoid products are allowed to be sold via these channels going forward.
While recreational marijuana has been legalized in Canada, the legality of CBD is still in question.
Shares of Emerald Health were down about 6% to US$2.02 in Tuesday Morning trading.
Contact Lenore Fedow at [email protected]